Breast cancer is one of the most frequent malignancies among women worldwide. Based on
clinical and molecular features of breast tumors, patients are treated with chemotherapy …

Breast cancer cells must avoid intrinsic and extrinsic cell death to relapse following
chemotherapy. Entering senescence enables survival from mitotic catastrophe, apoptosis …

Background Expanding therapeutic possibilities have improved disease-related prospects
for breast cancer patients. Pathological analysis on a tumor biopsy is the current reference …

Neoadjuvant chemotherapy (NACT) has become the standard of care for high‐risk breast
cancer, including triple‐negative (TNBC) and HER2‐positive disease. As a result, handling …

Purpose: A single arm, phase II trial of carboplatin, nab-paclitaxel, and pembrolizumab
(CNP) in metastatic triple-negative breast cancer (mTNBC) was designed to evaluate overall …

Background It has been established that clusterin is involved in the invasion of immune cells
in the tumor microenvironment, but it remains unknown how it promotes immune invasion in …

Immunotherapy has emerged as a revolutionary approach in cancer therapy, and recent
advancements hold significant promise for breast cancer (BCa) management. Employing the …

Abstract Background Immunohistochemical (IHC) PD-L1 expression is commonly employed
as predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC) …

In our phase Ib trial (ClinialTrials. gov Identifier: NCT03855358), benmelstobart (TQB2450),
a novel humanized IgG1 antibody against PD-L1, plus antiangiogenic multikinase inhibitor …

Background Immune checkpoint blockade (ICB) only works well for a certain subset of
patients with non-small cell lung cancer (NSCLC). Therefore, biomarkers for patient …